| Identification | Back Directory | [Name]
Baxdrostat | [CAS]
1428652-17-8 | [Synonyms]
Baxdrostat
Propanamide, N-[(8R)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl]- | [Molecular Formula]
C22H25N3O2 | [MOL File]
1428652-17-8.mol | [Molecular Weight]
363.45 |
| Chemical Properties | Back Directory | [Boiling point ]
697.6±55.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [solubility ]
DMSO : 250 mg/mL (687.85 mM; Need ultrasonic) | [form ]
Solid | [pka]
15.05±0.20(Predicted) | [color ]
Off-white to light yellow | [InChI]
InChI=1S/C22H25N3O2/c1-3-21(26)24-19-6-4-5-16-17(12-23-13-18(16)19)14-7-9-20-15(11-14)8-10-22(27)25(20)2/h7,9,11-13,19H,3-6,8,10H2,1-2H3,(H,24,26)/t19-/m1/s1 | [InChIKey]
VDEUDSRUMNAXJG-LJQANCHMSA-N | [SMILES]
C(N[C@H]1C2=C(CCC1)C(C1C=CC3=C(C=1)CCC(=O)N3C)=CN=C2)(=O)CC |
| Hazard Information | Back Directory | [Uses]
Baxdrostat is a novel aldosterone synthase Inhibitor for treatment resistant hypertension and systemic Hypertension. | [Mode of action]
The mechanism of action of baxdrostat as an aldosterone synthase inhibitor demonstrates the inextricable linkage between sodium and blood pressure regulation. Baxdrostat significantly decreases aldosterone in plasma and urine, while increasing plasma renin as a physiological compensatory change. |
|
|